Viemed(US:VMD)2025-11-05 21:38Financial Performance - Net revenues for Q3 2025 reached $71.9 million, a record for the company, representing a 24.0% increase from $58.0 million in Q3 2024[4] - Net income attributable to Viemed for Q3 2025 was $3.5 million, or $0.09 per diluted share[4] - Adjusted EBITDA for Q3 2025 totaled $16.1 million, reflecting a 15.5% increase compared to $13.9 million in Q3 2024[4] - Revenue for the three months ended September 30, 2025, was $71,914,000, a 24% increase from $58,004,000 in the same period of 2024[16] - Gross profit for the nine months ended September 30, 2025, reached $111,355,000, up 15% from $97,065,000 in 2024[16] - Net income for the three months ended September 30, 2025, was $3,600,000, compared to $3,905,000 in 2024, reflecting a decrease of 8%[16] - Adjusted EBITDA for the quarter ended September 30, 2025, was $16,121,000, an increase from $13,954,000 in the same quarter of 2024[20] - Revenue for the quarter ended September 30, 2025, was $71,914 million, an increase from $63,056 million in the previous quarter[27] - Gross profit for the same quarter was $41,345 million, with a gross profit margin of 57%[27] - Net income attributable to Viemed Healthcare, Inc. was $3,513 million, compared to $3,157 million in the previous quarter[27] - Adjusted EBITDA for the quarter was $16,121 million, up from $14,287 million in the previous quarter[27] Cash Flow and Expenses - The company maintains a cash balance of $11.1 million and has $38 million available under existing credit facilities as of September 30, 2025[4] - Net cash provided by operating activities for the nine months ended September 30, 2025, was $33,475,000, compared to $24,102,000 in 2024, representing a 39% increase[18] - Free cash flow for the trailing twelve months ended September 30, 2025, was $23,292,000, compared to $6,039,000 in the same period of 2024[25] - Cash and cash equivalents at the end of the period were $11,123,000, slightly down from $11,347,000 at the end of September 2024[18] - Cash and cash equivalents decreased to $11,123 million from $20,016 million in the previous quarter[27] Shareholder Actions - The company repurchased 1,706,380 common shares at a cost of $11.4 million, averaging $6.68 per share[4] Patient Metrics - Ventilator patient count increased to 12,372, an 8.8% rise from Q3 2024, while PAP therapy patient count rose to 31,891, a 63.7% increase[4] - The number of active ventilator patients was 12,372, an increase from 12,152 in the previous quarter[27] - The number of distinct patients billed for PAP therapy services rose to 31,891 from 26,260 in the previous quarter[27] - The number of distinct patients receiving supplies through the sleep resupply program increased to 33,518 from 25,246 in the previous quarter[27] Debt and Acquisitions - Long-term debt as of September 30, 2025, amounted to $19.6 million, up from $3.6 million at the end of 2024[14] - The acquisition of Lehan's Medical Equipment was completed on July 1, 2025, and has been accretive to net income and earnings per share since[4] Guidance - Full year 2025 net revenue guidance is updated to a range of $271 million to $273 million, down from the previous range of $271 million to $277 million[4] - Adjusted EBITDA guidance for 2025 is now expected to be between $60 million and $62 million, compared to the prior guidance of $59 million to $62 million[4] Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $34,871,000, up from $30,353,000 in 2024, indicating a 15% increase[16] Investment Performance - The company reported a net loss from investments of $0 for the three months ended September 30, 2025, compared to a gain of $96,000 in 2024[16] Share Statistics - The weighted average number of diluted shares outstanding for the three months ended September 30, 2025, was 40,495,761, compared to 40,779,414 in 2024[16]